Cargando…

CYP2B6*6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers

Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of the antimalarial drugs artemether and lumefantrine. Here we investigated the effect of CYP2B6*6 on the plasma pharmacokinetics of artemether, lumefantrine, and their metabolites in healthy volunteers. Thirty healthy and previously genotyp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdullahi, Sa'ad T., Soyinka, Julius O., Olagunju, Adeniyi, Bolarinwa, Rahman A., Olarewaju, Olusola J., Bakare‐Odunola, Moji T., Winterberg, Markus, Tarning, Joel, Owen, Andrew, Khoo, Saye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Pharmacogenomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028104/ https://www.ncbi.nlm.nih.gov/pubmed/31549442 http://dx.doi.org/10.1002/jcph.1527

Ejemplares similares

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes
por: Abdullahi, Sa’ad T., et al.
Publicado: (2020)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
por: Vourvahis, Manoli, et al.
Publicado: (2018)

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
por: Ali, Shabana, et al.
Publicado: (2010)

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline
por: Davenport, J Michael, et al.
Publicado: (2015)

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
por: Imamura, Chiyo K., et al.
Publicado: (2015)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
por: Marshall, Jean‐Claude, et al.
Publicado: (2021)

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations
por: Scotcher, Daniel, et al.
Publicado: (2017)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
por: Tarning, Joel, et al.
Publicado: (2022)

Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets
por: Belew, Sileshi, et al.
Publicado: (2020)

Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether‐Lumefantrine for Uncomplicated Malaria
por: Chotsiri, Palang, et al.
Publicado: (2019)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
por: Hoglund, Richard M, et al.
Publicado: (2015)

The clinical efficacy of artemether/lumefantrine (Coartem(®))
por: Makanga, Michael, et al.
Publicado: (2009)

Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2011)

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2011)

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
por: Peto, Thomas J, et al.
Publicado: (2022)

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
por: Banda, Clifford G., et al.
Publicado: (2018)

Quality Assessment of Artemether-Lumefantrine Samples and Artemether Injections Sold in the Cape Coast Metropolis
por: Prah, James, et al.
Publicado: (2016)

Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda
por: Tarning, Joel, et al.
Publicado: (2013)

Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria
por: Ehrhardt, Stephan, et al.
Publicado: (2009)

Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019
por: Dimbu, Pedro Rafael, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
por: Tchaparian, Eskouhie, et al.
Publicado: (2016)

Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria
por: Lohy Das, Jesmin, et al.
Publicado: (2018)

The Use of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax Malaria
por: Bassat, Quique
Publicado: (2011)

Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India
por: Valecha, Neena, et al.
Publicado: (2009)

Artemether/Lumefantrine for the Treatment of P. malariae in a Patient on Hemodialysis
por: Patrocínio-Jesus, Rita, et al.
Publicado: (2019)

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali
por: Diarra, Modibo, et al.
Publicado: (2021)

Adverse reaction to Coartem (artemether/lumefantrine) resulting in oculogyric crisis
por: Amponsah, Emmanuel Kofi, et al.
Publicado: (2021)

Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi
por: Nyangulu, Wongani, et al.
Publicado: (2023)

Pharmacopeial quality of artemether–lumefantrine anti-malarial agents in Uganda
por: Ocan, Moses, et al.
Publicado: (2023)

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
por: Sipilanyambe, Naawa, et al.
Publicado: (2008)

Malaria case-management under artemether-lumefantrine treatment policy in Uganda
por: Zurovac, Dejan, et al.
Publicado: (2008)

Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
por: Gürkov, Robert, et al.
Publicado: (2008)

Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children
por: Abdulla, Salim, et al.
Publicado: (2009)

Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?
por: Ogutu, Bernhards, et al.
Publicado: (2010)

Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania
por: Mugoyela, V, et al.
Publicado: (2011)

Formulation, process development and evaluation of artemether and lumefantrine soft gelatin capsule
por: Patel, A., et al.
Publicado: (2012)

Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda
por: Rulisa, Stephen, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_418015gm6e88moq1tcbbtekc5r